Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

被引：0
|
作者：
Fatemeh Karimi [1 ]
Mojtaba Aghaei [2 ]
Najmaldin Saki [1 ]
机构：
[1] Ahvaz Jundishapur University of Medical Sciences,
[2] Thalassemia & Hemoglobinopathy Research Center,undefined
[3] Health Research Institute,undefined
[4] Ahvaz Jundishapur University of Medical Sciences,undefined
来源：
Current Treatment Options in Oncology | 2025年 / 26卷 / 3期
关键词：
Polymorphisms; Treatment outcomes; Multiple Myeloma; Genetic markers; Personalized therapy; Biomarkers;
D O I：
10.1007/s11864-025-01295-8
中图分类号：
学科分类号：
摘要：
Multiple myeloma (MM) is a lymphoproliferative disorder that remains a fatal disease despite therapeutic advances.Treatment responses vary among MM patients due to biological factors, tumor characteristics, and genetic differences.Research indicates that genetic polymorphisms, particularly single nucleotide polymorphisms, may influence treatment efficacy and patient outcomes in MM.Ongoing research into these genetic factors may provide valuable insights into the underlying mechanisms of drug efficacy and resistance in this complex disease.
引用
下载
收藏
页码：197 / 212
页数：15
相关论文
共 50 条
  • [1] IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA
    Noonan, Kimberly
    Colson, Kathleen
    SEMINARS IN ONCOLOGY NURSING, 2017, 33 (03) : 279 - 291
  • [2] Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma
    Kashiwazaki, Sho
    Kamiko, Satoshi
    Uozaki, Ryo
    Yamamoto, Tomofumi
    Ichikawa, Daiju
    Hattori, Yutaka
    Matsushita, Maiko
    Hirao, Maki
    Kunieda, Hisako
    Yamazaki, Kohei
    BLOOD, 2018, 132
  • [3] EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Oostvogels, R.
    Jak, M.
    Minnema, M. C.
    HAEMATOLOGICA, 2018, 103 : 33 - 33
  • [4] Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
    Yalniz, Fevzi Firat
    Akkoc, Nihan
    Salihoglu, Ayse
    Ar, M. Cem
    Ongoren, Seniz
    Eskazan, A. Emre
    Soysal, Teoman
    Aydin, Yildiz
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 233 - 238
  • [5] Immunomodulatory drugs in the treatment of multiple myeloma
    Abe, Yu
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 695 - 702
  • [6] Proteasome inhibitors in the treatment of multiple myeloma
    McBride, Ali
    Ryan, Patricia Y.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (03) : 339 - 358
  • [7] Proteasome inhibitors in the treatment of multiple myeloma
    J J Shah
    R Z Orlowski
    Leukemia, 2009, 23 : 1964 - 1979
  • [8] Proteasome Inhibitors for the Treatment of Multiple Myeloma
    Ito, Shigeki
    CANCERS, 2020, 12 (02)
  • [9] Proteasome inhibitors for the treatment of multiple myeloma
    Scalzulli, Emilia
    Grammatico, Sara
    Vozella, Federico
    Petrucci, Maria Teresa
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 375 - 386
  • [10] Proteasome inhibitors in the treatment of multiple myeloma
    Shah, J. J.
    Orlowski, R. Z.
    LEUKEMIA, 2009, 23 (11) : 1964 - 1979
12345